Collectively, this suggests that a rationally designed ligand-independent TREM-2 inhibitory peptide sequence IA9 can be a promising alternative to ligand-dependent anti-TREM-2 mAbs to modulate local inflammation in the management of RA, IBD, cancer and, probably, other inflammatory diseases. Here, TREM2 is linked to cancer.